Table 1 Baseline demographics
Placebo N = 118 | Etoricoxib 60 mg N = 818 | Etoricoxib 90 mg N = 468 | Total N = 1404 | |
|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | |
Gender | ||||
Female | 100 (84.7) | 677 (82.8) | 395 (84.4) | 1172 (83.5) |
Age (Years) | ||||
Mean (SD) | 53.6 (11.0) | 53.8 (11.9) | 54.0 (12.3) | 53.8 (12.0) |
Min-Max Age | 27 – 80 | 18 – 83 | 19 – 84 | 18 – 84 |
Race | ||||
White | 85 (72.0) | 626 (76.5) | 348 (74.4) | 1059 (75.4) |
Asian | 16 (13.6) | 93 (11.4) | 55 (11.8) | 164 (11.7) |
Multi-racial | 10 (8.5) | 74 (9.0) | 42 (9.0) | 126 (9.0) |
Black | 4 (3.4) | 17 (2.1) | 12 (2.6) | 33 (2.4) |
Other | 3 (2.5) | 8 (1.0) | 11 (2.4) | 22 (1.6) |
Duration of RA (Years) | ||||
Mean (SD) | 4.2 (4.3) | 5.7 (6.7) | 5.8 (6.5) | 5.6 (6.5) |
ARA Functional Class | ||||
Class I | 18 (15.3) | 138 (16.9) | 79 (16.9) | 235 (16.7) |
Class II | 76 (64.4) | 535 (65.4) | 314 (67.1) | 925 (65.9) |
Class III | 24 (20.3) | 145 (17.7) | 75 (16.0) | 244 (17.4) |
Biologics User | 16 (13.6) | 113 (13.8) | 64 (13.7) | 193 (13.7) |
Methotrexate User | 43 (36.4) | 285 (34.8) | 170 (36.3) | 498 (35.5) |
Low-dose Corticosteroid User | 25 (21.2) | 208 (25.4) | 126 (26.9) | 359 (25.6) |
DMARD User | 56 (47.5) | 363 (44.4) | 219 (46.8) | 638 (45.4) |
DMARD or Corticosteroid | 61 (51.7) | 425 (52.0) | 247 (52.8) | 733 (52.2) |